---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032946"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2026-08-14T11:55:46+00:00"
generated_at: "2026-08-14T12:00:15.940432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galectin reports Q2 net loss $9.2M; FDA agrees on Phase 3 design for belapectin

## Summary
- Net loss $9.2M ($0.14/share) vs $7.6M ($0.12/share) in Q2 2025; R&D $2.1M, G&A $1.8M.
- FDA alignment on Phase 3 trial design for belapectin in MASH cirrhosis; protocol submission expected 3Q 2026.
- Chairman Richard Uihlein converted $105.8M debt (principal $91M + interest $14.8M) into 34.4M shares, effective July 31, 2026.
- Cash $13.2M at June 30, 2026; $10M line of credit available; cash runway through June 2027.
- NAVIGATE trial data published in Hepatology and Gastro Hep Advances; EASL presentations.

## SEC filing metadata
- accession: 0001140361-26-032946
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2026-08-14T11:55:46+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/0001140361-26-032946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032946
- JSON: https://secwatch.observer/filing/0001140361-26-032946.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.